Eli Lilly to support production of diabetes drugs with USD 450m investment
The US-based drugmaker has now committed around USD 4bn to new manufacturing facilities in North Carolina.
by marketwire, translated by daniel pedersen
Eli Lilly is planning to invest an additional USD 450m to expand its manufacturing capacity located in the Research Triangle in North Carolina.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk to invest EUR 130m in French factory
For subscribers
